Spruce Biosciences (SPRB) Times Interest Earned (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Times Interest Earned of -$1.18 for Q1 2026, up 99.71% year-over-year from -$0.59 in Q1 2025, and down 100.17% quarter-over-quarter from $693.75 in Q4 2025.
Spruce Biosciences (SPRB) Times Interest Earned (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Times Interest Earned for 8 consecutive years, with -$1.18 the latest figure, recorded in Q1 2026.
- In Q1 2026, Times Interest Earned rose 99.71% year-over-year to -$1.18; the TTM figure through Mar 2026 stood at -$3.36 (up 99.05% YoY), while the FY2025 annual figure was -$11.21, up 93.13% from the prior year.
- Times Interest Earned fell to -$1.18 in Q1 2026 per SPRB's latest filing, from $693.75 in the prior quarter.
- Across five years, Times Interest Earned topped out at $925.92 in Q4 2024 and bottomed at -$433.11 in Q3 2025.
- Historically, Times Interest Earned has averaged -$12.3 across 5 years, with a median of -$92.83 in 2025.
- Annual changes were most pronounced in 2022 — Times Interest Earned sank 4446.48% — and 2024, when it jumped 979.15%.
- Spruce Biosciences' Times Interest Earned stood at -$60.25 in 2022, then slumped by 74.81% to -$105.32 in 2023, then surged by 979.15% to $925.92 in 2024, then slipped by 25.07% to $693.75 in 2025, then slumped by 100.17% to -$1.18 in 2026.
- Business Quant data shows SPRB's Times Interest Earned at -$1.18 in Q1 2026, $693.75 in Q4 2025, and -$433.11 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | -15.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.74 |
| Mar 31, 2026 | -1.18 |
| Dec 31, 2025 | 693.75 |
| Sep 30, 2025 | -433.11 |
| Jun 30, 2025 | -92.83 |
| Mar 31, 2025 | -402.56 |
| Dec 31, 2024 | 925.92 |
| Sep 30, 2024 | -132.51 |
| Jun 30, 2024 | -120.92 |
| Mar 31, 2024 | -130.24 |
| Dec 31, 2023 | -105.32 |
| Sep 30, 2023 | -114.77 |
| Jun 30, 2023 | -110.02 |
| Mar 31, 2023 | -60.27 |
| Dec 31, 2022 | -60.25 |
| Sep 30, 2022 | -13.22 |
| Jun 30, 2022 | -28.98 |
| Mar 31, 2022 | -22.65 |
| Dec 31, 2021 | -40.78 |
| Sep 30, 2021 | -1.60 |